IL107250A - Dna molecules involved in programmed cell death, proteins encoded thereby and methods and compositions using said dna molecules and proteins - Google Patents

Dna molecules involved in programmed cell death, proteins encoded thereby and methods and compositions using said dna molecules and proteins

Info

Publication number
IL107250A
IL107250A IL10725093A IL10725093A IL107250A IL 107250 A IL107250 A IL 107250A IL 10725093 A IL10725093 A IL 10725093A IL 10725093 A IL10725093 A IL 10725093A IL 107250 A IL107250 A IL 107250A
Authority
IL
Israel
Prior art keywords
sequence
dna
protein
dap
triplet
Prior art date
Application number
IL10725093A
Other languages
English (en)
Other versions
IL107250A0 (en
Inventor
Adi Kimchi
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Priority to IL10725093A priority Critical patent/IL107250A/en
Publication of IL107250A0 publication Critical patent/IL107250A0/xx
Priority to JP51203495A priority patent/JP3791927B2/ja
Priority to EP95900994A priority patent/EP0804613B1/de
Priority to DE69434315T priority patent/DE69434315T2/de
Priority to PCT/US1994/011598 priority patent/WO1995010630A1/en
Priority to CA002174136A priority patent/CA2174136A1/en
Priority to ES95900994T priority patent/ES2240971T3/es
Priority to AT95900994T priority patent/ATE291619T1/de
Priority to EP05005471A priority patent/EP1586642A2/de
Priority to US08/631,097 priority patent/US5968816A/en
Priority to US08/810,712 priority patent/US6160106A/en
Publication of IL107250A publication Critical patent/IL107250A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/23—Aspartic endopeptidases (3.4.23)
    • C12Y304/23005—Cathepsin D (3.4.23.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL10725093A 1993-10-12 1993-10-12 Dna molecules involved in programmed cell death, proteins encoded thereby and methods and compositions using said dna molecules and proteins IL107250A (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
IL10725093A IL107250A (en) 1993-10-12 1993-10-12 Dna molecules involved in programmed cell death, proteins encoded thereby and methods and compositions using said dna molecules and proteins
EP05005471A EP1586642A2 (de) 1993-10-12 1994-10-12 Tumorsupressorgene, durch sie kodierte Proteine und die Verwendung besagter Gene und Proteine
PCT/US1994/011598 WO1995010630A1 (en) 1993-10-12 1994-10-12 Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins
EP95900994A EP0804613B1 (de) 1993-10-12 1994-10-12 Dap-2 tumorsupressorgen, durch sie kodierte protein und verwendung besagter gen und protein
DE69434315T DE69434315T2 (de) 1993-10-12 1994-10-12 Dap-2 tumorsupressorgen, durch sie kodierte protein und verwendung besagter gen und protein
JP51203495A JP3791927B2 (ja) 1993-10-12 1994-10-12 腫瘍サプレッサー遺伝子，それらによってコードされる蛋白質ならびにそれらの遺伝子および蛋白質の使用
CA002174136A CA2174136A1 (en) 1993-10-12 1994-10-12 Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins
ES95900994T ES2240971T3 (es) 1993-10-12 1994-10-12 Genes supresores de tumores, proteinas codificadas por ellos y uso de dichos genes y proteinas.
AT95900994T ATE291619T1 (de) 1993-10-12 1994-10-12 Dap-2 tumorsupressorgen, durch sie kodierte protein und verwendung besagter gen und protein
US08/631,097 US5968816A (en) 1993-10-12 1996-04-12 Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins
US08/810,712 US6160106A (en) 1993-10-12 1997-03-03 Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL10725093A IL107250A (en) 1993-10-12 1993-10-12 Dna molecules involved in programmed cell death, proteins encoded thereby and methods and compositions using said dna molecules and proteins

Publications (2)

Publication Number Publication Date
IL107250A0 IL107250A0 (en) 1994-01-25
IL107250A true IL107250A (en) 2001-08-08

Family

ID=11065332

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10725093A IL107250A (en) 1993-10-12 1993-10-12 Dna molecules involved in programmed cell death, proteins encoded thereby and methods and compositions using said dna molecules and proteins

Country Status (8)

Country Link
EP (2) EP1586642A2 (de)
JP (1) JP3791927B2 (de)
AT (1) ATE291619T1 (de)
CA (1) CA2174136A1 (de)
DE (1) DE69434315T2 (de)
ES (1) ES2240971T3 (de)
IL (1) IL107250A (de)
WO (1) WO1995010630A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6160106A (en) * 1993-10-12 2000-12-12 Yeda Research & Development Co., Ltd. Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins
US6472170B1 (en) * 1996-08-02 2002-10-29 Dana-Farber Cancer Institute BCL-Xy, a novel BCL-X isoform, and uses related thereto
US5776759A (en) * 1996-09-26 1998-07-07 Incyte Pharmaceuticals, Inc. Two novel human cathepsin proteins
US6225103B1 (en) * 1996-11-20 2001-05-01 Oklahoma Medical Research Foundation Cloning and characterization of napsin
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
JP2002504381A (ja) * 1998-02-27 2002-02-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 遺伝子治療による炎症性細胞の自己調節アポトーシス
JP2002506651A (ja) * 1998-03-16 2002-03-05 イントロジェン・セラピューティクス，インコーポレイテッド 多重遺伝子ベクター
US7026148B1 (en) 1998-06-15 2006-04-11 Yeda Research And Development Co., Ltd. DAP-kinase related protein
GB2354522B (en) * 1998-06-15 2004-01-21 Yeda Res & Dev DAP-kinase related protein
AU5128999A (en) * 1998-07-24 2000-02-14 Yeda Research And Development Co. Ltd. Prevention of metastasis with 5-aza-2'-deoxycytidine
AU1082701A (en) * 1999-10-13 2001-04-23 Yeda Research And Development Co. Ltd. Short segments of dap-kinase
US6965023B2 (en) 2000-11-17 2005-11-15 The Burnham Institute Death domain proteins
WO2002040680A2 (en) * 2000-11-17 2002-05-23 The Burnham Institute Death domain proteins
JPWO2003083101A1 (ja) * 2002-03-29 2005-08-04 三菱ウェルファーマ株式会社 Ｄａｐキナーゼの結晶、それを用いたｄａｐキナーゼをターゲットとする薬物候補分子のスクリーニング方法及びそれにより得られる医薬
EP2545170A1 (de) 2010-03-11 2013-01-16 Yeda Research And Development Co. Ltd. Zelltod-assoziierte protein-1-varianten und verwendung zur modulation von autophagie
US9149523B2 (en) 2010-12-15 2015-10-06 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer and neurodegenerative diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4542096A (en) * 1983-02-25 1985-09-17 President And Fellows Of Harvard College Detecting rearranged human c-myc DNA fragments associated with oncogenes
US4798787A (en) * 1984-09-19 1989-01-17 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US5015570A (en) * 1988-05-13 1991-05-14 Molecular Therapeutics, Inc. Molecular diagnosis of Alzheimer Disease
NO312681B1 (no) * 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
GB9122051D0 (en) * 1991-10-17 1991-11-27 Univ Nottingham Medicines

Also Published As

Publication number Publication date
JPH09505992A (ja) 1997-06-17
EP0804613A1 (de) 1997-11-05
EP0804613B1 (de) 2005-03-23
JP3791927B2 (ja) 2006-06-28
ES2240971T3 (es) 2005-10-16
ATE291619T1 (de) 2005-04-15
CA2174136A1 (en) 1995-04-20
WO1995010630A1 (en) 1995-04-20
EP1586642A2 (de) 2005-10-19
DE69434315T2 (de) 2006-03-30
DE69434315D1 (de) 2005-04-28
EP0804613A4 (de) 1999-07-14
IL107250A0 (en) 1994-01-25

Similar Documents

Publication Publication Date Title
EP0804613B1 (de) Dap-2 tumorsupressorgen, durch sie kodierte protein und verwendung besagter gen und protein
Nishimura et al. Molecular cloning and characterization of mammalian homologues of vesicle-associated membrane protein-associated (VAMP-associated) proteins
US7759476B2 (en) Double-stranded RNAS directed to IKK-2
CA2284859C (en) Nucleic acid molecule for a human skeletal muscle-specific receptor
JP2008301815A (ja) 刺激誘導性Ｉ（κ）Ｂキナーゼ［ＩＫＫ］シグナルソーム
US6077685A (en) Tumor suppressor merlin and antibodies thereof
CA2301801A1 (en) Elongation factor-2 kinase (ef-2 kinase) and methods of use therefor
EP0981610B1 (de) Zusammensetzung für die behandlung von erkrankungen, die mit apoptose einhergehen
CA2230795A1 (en) Cyclin e variants and use thereof
US6172195B1 (en) IKAP proteins and methods
US5968816A (en) Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins
US5559019A (en) Protein serine kinase, SRPK1
Ying et al. Cloning and characterization of F-LANa, upregulated in human liver cancer
CA2262479A1 (en) Brca1 associated protein (bap-1) and uses therefor
WO1998005968A9 (en) Brca1 associated protein (bap-1) and uses therefor
Nishi et al. Neurofibromatosis 2 gene has novel alternative splicings which controls intracellular protein binding
DEGUEN et al. The NF2 Tumor Suppressor Gene

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees